News Conference News ESC 2019 New PURE Insights: CVD Deaths Dip in Rich Nations Amid Risk-Factor Surprises Michael O'Riordan September 04, 2019
News Daily News Ezetimibe With Statin Therapy: Biggest Bang in Higher-Risk ACS Patients Michael O'Riordan August 22, 2019
News Conference News ESC 2019 ESC 2019: Antiplatelets in Diabetes, CAD and A-fib, an ARNI in HFpEF, Staged Complete PCI, and More Shelley Wood August 22, 2019
News Conference News SCCT 2019 Time to Ease Up on Prior Authorization for PCSK9 Inhibitors? Yael L. Maxwell July 15, 2019
News Daily News Most Supplements and Diets Don’t Lower CVD or Mortality Risks Michael O'Riordan July 09, 2019
News Daily News Elevated Non-HDL Cholesterol Levels Persist From Youth to Middle Age Marcus A. Banks July 03, 2019
News Daily News High Levels of Lp(a) Linked to Increased Ischemic Stroke Risk Michael O'Riordan July 01, 2019
News Conference News EAS 2019 CHD Mortality Significantly Elevated in Patients With Severe FH Michael O'Riordan May 29, 2019
News Daily News Familial Hypercholesterolemia Seen in 10% of Young MI Patients Michael O'Riordan May 15, 2019
News Daily News No Need for Niacin? Meta-analysis Argues the End Is Nigh Yael L. Maxwell April 22, 2019
News Conference News ACC 2019 REDUCE-IT Subanalysis: Icosapent Ethyl Reduces Total and Recurrent CV Events Yael L. Maxwell March 22, 2019
News Daily News Rising Number of CV-Related Maternal Deaths Spurs Need for #CardioObstetrics Caitlin E. Cox February 27, 2019
News Daily News Most Cardiovascular Drugs Can Be Safely Used in Pregnancy, Review Suggests Todd Neale February 01, 2019
News Daily News Ethnic Variations in Lp(a) Concentrations Challenge Current Risk Thresholds Yael L. Maxwell January 25, 2019
News Daily News Dose-Response Benefits for Fiber Intake Seen Across Wide Swath of Acquired Diseases Shelley Wood January 15, 2019
News Daily News Angina Without Obstructive Stenosis: No Longer a ‘Black Box’ Mystery, Say Experts Michael O'Riordan November 23, 2018
News Conference News AHA 2018 Alirocumab Should Be Priced at $6,300 Annually: ODYSSEY Cost-Effectiveness Study Michael O'Riordan November 15, 2018